Serum sPD ‐1 and sPD ‐ L1 as predictive biomarkers for HBsAg clearance in HBeAg ‐negative CHB patients undergoing IFN ‐based therapy
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18131 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Xiyao Chen and 9 co-authors. Institution: Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. Major MEDLINE topics: Hepatitis B, Chronic, Hepatitis B Surface Antigens, B7-H1 Antigen, Antiviral Agents. Cited 8 times so far (Crossref); 60 references. Funded by: Sun Yat-Sen University Clinical Research 5010 Program.
Abstract (original language)
Background and Aims For chronic hepatitis B (CHB) patients, there is still a need to improve hepatitis B surface antigen (HBsAg) clearance rates. This study aimed to assess the predictive effectiveness of soluble programmed cell death‐1 (sPD‐1) and soluble programmed cell death ligand‐1 (sPD‐L1) for HBsAg clearance in HBeAg‐negative CHB patients undergoing peginterferon (Peg‐IFN)‐based antiviral treatment.
Methods
This study encompassed 280 patients undergoing treatment with Peg‐IFNα. Serum levels of sPD‐1 and sPD‐L1 were measured using ELISA kits at baseline, as well as at 12, 24 and 48 weeks. The primary endpoint of the study was the determination of HBsAg clearance at 48 weeks. Logistic regression analysis was employed to identify predictors of HBsAg clearance.
Results
The clearance group demonstrated significantly lower serum sPD‐L1 levels compared to the non‐clearance group. While both groups exhibited an increase in sPD‐1 levels, only the clearance group showed a rise in sPD‐L1 levels. Multivariate analysis identified sPD‐L1 increase at 24 weeks, and HBsAg decline at 24 weeks as predictors for HBsAg clearance at 48 weeks. The combined use of these indicators showed a predictive performance for HBsAg clearance with an AUROC of 0.907 (95% CI: 0.861–0.953, p < 0.001).
Conclusions
The study revealed an inverse relationship between the trends of sPD‐1/sPD‐L1 and HBsAg clearance during combined IFN and NAs treatment. Moreover, the magnitude of HBsAg reduction and sPD‐L1 increase emerged as significant predictors for HBsAg clearance.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID profiles: Xiyao Chen, Zhiliang Gao, Chan Xie
Funding
- Sun Yat-Sen University Clinical Research 5010 Program
Cite
APA
Chen, X., Zhang, B., Song, X., Qian, T., Zheng, X., Zhang, Y., Xu, W., Gao, Z., Peng, L., & Xie, C. (2024). Serum sPD ‐1 and sPD ‐ L1 as predictive biomarkers for HBsAg clearance in HBeAg ‐negative CHB patients undergoing IFN ‐based therapy. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18131
Vancouver
Chen X, Zhang B, Song X, Qian T, Zheng X, Zhang Y, et al. Serum sPD ‐1 and sPD ‐ L1 as predictive biomarkers for HBsAg clearance in HBeAg ‐negative CHB patients undergoing IFN ‐based therapy. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18131
BibTeX
@article{Chen2024,
author = {Chen, Xiyao and Zhang, Boxiang and Song, Xin and Qian, Tinglin and Zheng, Xingrong and Zhang, Yeqiong and Xu, Wenxiong and Gao, Zhiliang and Peng, Liang and Xie, Chan},
title = {Serum sPD ‐1 and sPD ‐ L1 as predictive biomarkers for HBsAg clearance in HBeAg ‐negative CHB patients undergoing IFN ‐based therapy},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18131}
}
EUVIMED